Showing results (241-250 of 280) with videos related to

Sort By:
Pageof 28
International Journal of Cancer|December 31, 2013
Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humansSimona Bramante, Anniina Koski, Anja Kipar, et al.
Oncoimmunology|September 14, 2020
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibitionVictor Cervera-Carrascon, Dafne C A Quixabeira, Joao Manuel Santos, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 3, 2013
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patientsIlkka Liikanen, Laura Ahtiainen, Mari L M Hirvinen, et al.
Molecular Therapy Oncolytics|January 26, 2023
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumorsSaru Basnet, Joao M Santos, Dafne C A Quixabeira, et al.
International Journal of Cancer|August 13, 2009
Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiationMaria Rajecki, Taija af Hällström, Tanja Hakkarainen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumorsPetri Nokisalmi, Sari Pesonen, Sophie Escutenaire, et al.
The Lancet. Oncology|January 9, 2013
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trialPirkko-Liisa Kellokumpu-Lehtinen, Ulrika Harmenberg, Timo Joensuu, et al.
Human Gene Therapy|December 22, 2010
A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patientsKenneth H Kim, Michael J Ryan, James E Estep, et al.
International Journal of Cancer|June 2, 2011
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumorsSari Pesonen, Iulia Diaconu, Vincenzo Cerullo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 24, 2024
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokineSaru Basnet, Mirte Van der Heijden, Dafne C A Quixabeira, et al.
Pageof 28